Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration Portfolio News / By Karina Tin July 10, 2024 Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration Read More »
Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy Portfolio News / By Karina Tin July 10, 2024 Tr1X Announces First Patient Dosed in Proof of Concept GvHD Trial Evaluating TRX103, a First-in-Class Type 1 Treg (Tr1) Cell Therapy Read More »
Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors Portfolio News / By Karina Tin July 1, 2024 Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors Read More »
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy Portfolio News / By Karina Tin June 18, 2024 Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy Read More »
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Portfolio News / By Karina Tin June 16, 2024 Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Read More »
InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Diseases Portfolio News / By Karina Tin June 13, 2024 InduPro Announces $85 Million Series A Financing, Appoints Prakash Raman, Ph.D. as CEO to Advance Next-Generation, Proximity-Based Protein Therapeutics for the Treatment of Cancer and Autoimmune Diseases Read More »
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer Portfolio News / By Karina Tin June 11, 2024 Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer Read More »
Incyte Completes Acquisition of Escient Pharmaceuticals Portfolio News / By Karina Tin May 30, 2024 Incyte Completes Acquisition of Escient Pharmaceuticals Read More »
A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Portfolio News / By Karina Tin May 29, 2024 A2 Bio Highlights Progress of CAR T-Cell Clinical Programs in Three Poster Presentations during the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting Read More »
Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer Portfolio News / By Karina Tin May 28, 2024 Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer Read More »
